(NASDAQ: VXRT) Vaxart's forecast annual revenue growth rate of 111.69% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Vaxart's revenue in 2024 is $7,379,000.On average, 1 Wall Street analysts forecast VXRT's revenue for 2024 to be $6,797,991,844, with the lowest VXRT revenue forecast at $6,797,991,844, and the highest VXRT revenue forecast at $6,797,991,844. On average, 1 Wall Street analysts forecast VXRT's revenue for 2025 to be $11,179,306,281, with the lowest VXRT revenue forecast at $11,179,306,281, and the highest VXRT revenue forecast at $11,179,306,281.
In 2026, VXRT is forecast to generate $11,831,287,596 in revenue, with the lowest revenue forecast at $2,016,795,534 and the highest revenue forecast at $21,645,779,658.